Cargando…

Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review

INTRODUCTION: Heterozygous familial hypercholesterolaemia (heFH) is the most common monogenic cause of premature atherosclerotic cardiovascular disease. The precise diagnosis of heFH is established by genetic testing. This systematic review will investigate the risk factors that predict cardiovascul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mansilla-Rodríguez, María Elena, Romero-Jimenez, Manuel J, Rigabert Sánchez-Junco, Alina, Gutierrez-Cortizo, Eva Nadiedja, Sánchez-Ramos, José Luis, Mata, Pedro, Pang, Jing, Watts, Gerald F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069512/ https://www.ncbi.nlm.nih.gov/pubmed/36990476 http://dx.doi.org/10.1136/bmjopen-2022-065551

Ejemplares similares

Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
por: Akioyamen, Leo E, et al.
Publicado: (2017)

Coronary artery calcium among patients with heterozygous familial hypercholesterolaemia
por: Tada, Hayato, et al.
Publicado: (2023)

Prevalence, awareness, treatment and control of hypertension, diabetes and hypercholesterolaemia among adults in Dande municipality, Angola
por: João, M Pedro, et al.
Publicado: (2018)

How Can Implementation Science Improve the Care of Familial Hypercholesterolaemia?
por: Sarkies, Mitchell, et al.
Publicado: (2023)

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
por: Blom, Dirk J., et al.
Publicado: (2018)

Prevalence of cardiovascular events in genetically confirmed versus unconfirmed familial hypercholesterolaemia
por: Khan, Tina Z, et al.
Publicado: (2020)

CEPHEUS SA: a South African survey on the under-treatment of hypercholesterolaemia
por: Raal, Frederick Johan, et al.
Publicado: (2011)

An online questionnaire survey of UK general practitioners’ knowledge and management of familial hypercholesterolaemia
por: Kwok, See, et al.
Publicado: (2016)

An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the “Ten Countries Study”
por: Pang, Jing, et al.
Publicado: (2017)

Cardiovascular risk stratification in familial hypercholesterolaemia
por: Sharifi, Mahtab, et al.
Publicado: (2016)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis
por: Kinnear, Fiona J, et al.
Publicado: (2019)

Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
por: Descamps, Olivier S., et al.
Publicado: (2017)

Genetic Architecture of Familial Hypercholesterolaemia
por: Sharifi, Mahtab, et al.
Publicado: (2017)

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials
por: Cupido, Arjen J, et al.
Publicado: (2020)

Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review
por: Mohd Nor, Noor Shafina, et al.
Publicado: (2019)

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
por: Raal, Frederick, et al.
Publicado: (2023)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
por: Matta, Anthony, et al.
Publicado: (2023)

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
por: Ramaswami, Uma, et al.
Publicado: (2020)

Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel
por: Bjelakovic, Bojko, et al.
Publicado: (2021)

Improving detection and management of familial hypercholesterolaemia in Australian general practice
por: Brett, Tom, et al.
Publicado: (2021)

Association between CVDs and initiation and adherence to statin treatment in patients with newly diagnosed hypercholesterolaemia: a retrospective cohort study
por: Ryou, In Sun, et al.
Publicado: (2021)

Familial hypercholesterolaemia: a study protocol for identification and investigation of potential causes and markers of subclinical coronary artery disease in the Faroe Islands
por: Borg, Sanna á, et al.
Publicado: (2022)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective
por: Watts, Gerald F., et al.
Publicado: (2021)

Hypercholesterolaemia in a vegan.
por: Duggan, B., et al.
Publicado: (1997)

Nutraceuticals in hypercholesterolaemia: an overview
por: Santini, Antonello, et al.
Publicado: (2016)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
por: Borissov, Borislav, et al.
Publicado: (2017)

Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician
por: Horton, Ari E, et al.
Publicado: (2022)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
por: Neil, Andrew, et al.
Publicado: (2008)

The genetics and screening of familial hypercholesterolaemia
por: Henderson, Raymond, et al.
Publicado: (2016)

Tendon xanthomas in familial hypercholesterolaemia
por: Bharath, Gopinath, et al.
Publicado: (2020)

Macrophages of genetically characterized familial hypercholesterolaemia patients show up‐regulation of LDL‐receptor‐related proteins
por: Escate, Rafael, et al.
Publicado: (2016)

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
por: Pećin, Ivan, et al.
Publicado: (2017)

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK
por: Kerr, Marion, et al.
Publicado: (2017)

Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration
por: Bellgard, Matthew I, et al.
Publicado: (2017)

How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment? A systematic review of qualitative evidence protocol
por: Kinnear, Fiona J., et al.
Publicado: (2018)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1jno9tru6vcjeg67cgojb9acek